Insider · CIK 0001770823
Margaret McLoughlin
Files at QNCX (Quince Therapeutics, Inc.). First filing -, latest -.
Margaret McLoughlin files SEC Form 4 as director at QNCX (Quince Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Margaret McLoughlin has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | QNCX Quince Therapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +19,547 | $0.00 | $0 | 19,547 | Jan 21, 2026 |
| Jun 4, 2025 | QNCX Quince Therapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +27,000 | $0.00 | $0 | 27,000 | Jun 6, 2025 |
Questions about Margaret McLoughlin
Answered from the filings on this page, as of the latest one.
Is Margaret McLoughlin buying or selling?
Margaret McLoughlin has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Margaret McLoughlin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Margaret McLoughlin has 0.
Where does Margaret McLoughlin file Form 4?
Margaret McLoughlin has filed Form 4 at QNCX (Quince Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.